Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials

British Journal of Pharmacology

Volumn 174, Issue 22, 2017, Pages 3973-3985

  Catapano, Alberico Luigi ^a,b   Pirillo, Angela ^c   Norata, Giuseppe Danilo ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c Bassini Hospital   (Italy)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CHOLESTEROL; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INFLAMMATORY INFILTRATE; LIPID METABOLISM; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; TREATMENT DURATION; VASCULITIS; METABOLISM;

CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INFLAMMATION;

EID: 85018421843     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13805     Document Type: Review

References (127)

1. Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW et al. (2015). Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol 115: 288–292.
2. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R et al. (2010). Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105: 1371–1377 e1371.
3. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW et al. (2013). Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 111: 1394–1400.
4. Ahmad HM, Sarhan EM, Komber U (2014). Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus. Rheumatol Int 34: 617–623.
5. Albert MA, Danielson E, Rifai N, Ridker PM (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64–70.
6. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
7. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
8. Amezaga Urruela M, Suarez-Almazor ME (2012). Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep 14: 428–437.
9. Ammirati E, Bozzolo EP, Contri R, Baragetti A, Palini AG, Cianflone D et al. (2014). Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis: NMCD 24: 751–759.
10. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC et al. (2004). Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177: 161–166.
11. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A (2000). Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 23 (Suppl 2): B72–B78.
12. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R et al. (2015). Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 36: 1186–1194.
13. Choudhury RP, Birks JS, Mani V, Biasiolli L, Robson MD, L'Allier PL et al. (2016). Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol 68: 1769–1780.
14. Chu CS, Wang YC, Lu LS, Walton B, Yilmaz HR, Huang RY et al. (2013). Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One 8: e70533.
15. Cirillo P, Golino P, Calabro P, Cali G, Ragni M, De Rosa S et al. (2005). C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68: 47–55.
16. Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J (2012). Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71: 862–868.
17. de Carvalho JF, Bonfa E, Borba EF (2008). Systemic lupus erythematosus and “lupus dyslipoproteinemia”. Autoimmun Rev 7: 246–250.
18. Di Minno MN, Ambrosino P, Peluso R, Di Minno A, Lupoli R, Dentali F (2014). Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-alpha blockers: a meta-analysis of prospective studies. Ann Med 46: 73–83.
19. Diffenderfer MR, Schaefer EJ (2014). The composition and metabolism of large and small LDL. Curr Opin Lipidol 25: 221–226.
20. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357–1361.
21. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al. (2009). Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302: 37–48.
22. Emberson J, Bennett D, Link E, Parish S, Danesh J, Armitage J et al. (2011). C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469–476.
23. Fearon WF, Fearon DT (2008). Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 117: 2577–2579.
24. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S et al. (2006). Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 27: 1182–1190.
25. Flaim JD, Grundy JS, Baker BF, McGowan MP, Kastelein JJ (2014). Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc 3: e000560.
26. Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L et al. (2005). Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52: 192–200.
27. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454.
28. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM (1996). Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 16: 1000–1006.
29. Garcia-Gomez C, Bianchi M, de la Fuente D, Badimon L, Padro T, Corbella E et al. (2014). Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: a qualitative relationship? World J Orthop 5: 304–311.
30. Garcia MM, Varela CG, Silva PF, Lima PR, Goes PM, Rodrigues MG et al. (2016). Endothelial effect of statin therapy at a high dose versus low dose associated with ezetimibe. Arq Bras Cardiol 106: 279–288.
31. Gimbrone MA Jr, Garcia-Cardena G (2016). Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 118: 620–636.
32. Goldstein JL, Brown MS (2015). A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161: 161–172.
33. Grebe A, Latz E (2013). Cholesterol crystals and inflammation. Curr Rheumatol Rep 15: 313.
34. Grigore L, Raselli S, Garlaschelli K, Redaelli L, Norata GD, Pirillo A et al. (2013). Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. Eur J Clin Pharmacol 69: 341–346.
35. Haque S, Mirjafari H, Bruce IN (2008). Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 19: 338–343.
36. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D et al. (2015). Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386: 452–460.
37. Jasinska M, Owczarek J, Orszulak-Michalak D (2007). Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59: 483–499.
38. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S (2001). Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933–1935.
39. Joshi PH, Jacobson TA (2010). Therapeutic options to further lower C-reactive protein for patients on statin treatment. Curr Atheroscler Rep 12: 34–42.
40. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R et al. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132–140.
41. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K et al. (2011). Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 31: 451–456.
42. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR et al. (2004). Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169–1196.
43. Kinlay S (2007). Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49: 2003–2009.
44. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ et al. (2003). High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560–1566.
45. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD et al. (2008). Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 28: 142–147.
46. Kocarnik JM, Pendergrass SA, Carty CL, Pankow JS, Schumacher FR, Cheng I et al. (2014). Multiancestral analysis of inflammation-related genetic variants and C-reactive protein in the population architecture using genomics and epidemiology study. Circ Cardiovasc Genet 7: 178–188.
47. Koenig W (2013). High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 168: 5126–5134.
48. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al. (2005). Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111: 2356–2363.
49. Lane T, Wassef N, Poole S, Mistry Y, Lachmann HJ, Gillmore JD et al. (2014). Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 114: 672–676.
50. Libby P (2002). Inflammation in atherosclerosis. Nature 420: 868–874.
51. Libby P (2012). Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 2045–2051.
52. Linton MF, Yancey PG, Davies SS, Jerome WGJ, Linton EF, Vickers KC (2000). The role of lipids and lipoproteins in atherosclerosis [Updated 2015 Dec 24]In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from:. https://www.ncbi.nlm.nih.gov/books/NBK343489/.
53. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK (2009). Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119: 131–138.
54. Liu X, Teichtahl AJ, Wicks IP (2015). Interleukin-6 in rheumatoid arthritis – from the laboratory to the bedside. Curr Pharm Des 21: 2187–2197.
55. Lubrano V, Gabriele M, Puntoni MR, Longo V, Pucci L (2015). Relationship among IL-6, LDL cholesterol and lipid peroxidation. Cell Mol Biol Lett 20: 310–322.
56. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD et al. (2015). Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74: 694–702.
57. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, van der Loos CM et al. (2006). Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 59: 196–201.
58. Mihos CG, Pineda AM, Santana O (2014). Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res 88: 12–19.
59. Montecucco F, Favari E, Norata GD, Ronda N, Nofer JR, Vuilleumier N (2015). Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Handb Exp Pharmacol 224: 455–482.
60. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A et al. (2006). Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114: 281–288.
61. Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B et al. (2015). The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 36: 377–384.
62. Namiri-Kalantari R, Gao F, Chattopadhyay A, Wheeler AA, Navab KD, Farias-Eisner R et al. (2015). The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory. Biofactors 41: 153–159.
63. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P et al. (2011). Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365: 2078–2087.
64. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ et al. (2016). Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316: 2373–2384.
65. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. (2004). Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071–1080.
66. Norata GD, Ballantyne CM, Catapano AL (2013). New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 34: 1783–1789.
67. Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL (2016). Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res 112: 429–442.
68. Norata GD, Tibolla G, Catapano AL (2014). Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 54: 273–293.
69. Noveck R, Stroes ES, Flaim JD, Baker BF, Hughes S, Graham MJ et al. (2014). Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. J Am Heart Assoc. doi: 10.1161/JAHA.114.001084.
70. Nowak B, Madej M, Luczak A, Malecki R, Wiland P (2016). Disease activity, oxidized-LDL fraction and anti-oxidized LDL antibodies influence cardiovascular risk in rheumatoid arthritis. Adv Clin Exp Med 25: 43–50.
71. Olofsson PS, Sheikine Y, Jatta K, Ghaderi M, Samnegard A, Eriksson P et al. (2009). A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 73: 1531–1536.
72. Pasceri V, Willerson JT, Yeh ET (2000). Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165–2168.
73. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J et al. (2009). Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 103: 369–374.
74. Pepys MB, Hirschfield GM (2003). C-reactive protein: a critical update. J Clin Invest 111: 1805–1812.
75. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007). The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48: 751–762.
76. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ et al. (2013). C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 128: 2395–2403.
77. Qamar A, Rader DJ (2012). Effect of interleukin 1beta inhibition in cardiovascular disease. Curr Opin Lipidol 23: 548–553.
78. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R et al. (2015a). Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385: 341–350.
79. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L et al. (2015b). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385: 331–340.
80. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT et al. (2010). Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5: e11765.
81. Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO et al. (2011). Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 18: 704–716.
82. Ridker PM (2016). From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118: 145–156.
83. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. (2005). C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.
84. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
85. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. (2009). Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175–1182.
86. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. (2001). Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959–1965.
87. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999). Long-term effects of pravastatin on plasma concentration of C-reactive protein. Cholesterol Recurrent Events (CARE) Investigators Circ 100: 230–235.
88. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M et al. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489–1499.
89. Roma P, Bernini F, Fogliatto R, Bertulli SM, Negri S, Fumagalli R et al. (1992). Defective catabolism of oxidized LDL by J774 murine macrophages. J Lipid Res 33: 819–829.
90. Ross R (1999). Atherosclerosis – an inflammatory disease. N Engl J Med 340: 115–126.
91. Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH et al. (2006). Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol 26: 1150–1155.
92. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med https://doi.org/10.1056/NEJMoa1615664.
93. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J et al. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500–1509.
94. Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, Ferretti G et al. (2016). Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol 81: 1175–1190.
95. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN et al. (2012). Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379: 1205–1213.
96. Satoh M, Takahashi Y, Tabuchi T, Minami Y, Tamada M, Takahashi K et al. (2015). Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci (Lond) 129: 93–105.
97. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B (2009). How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 102: 215–222.
98. Settergren M, Bohm F, Ryden L, Pernow J (2008). Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753–1760.
99. Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P et al. (2013). Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol 62: 717–729.
100. Signorelli SS, Fiore V, Malaponte G (2014). Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Med 33: 777–783.
101. Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA et al. (2015). Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the collaborative atorvastatin diabetes trial. Diabetologia 58: 1494–1502.
102. Sorci-Thomas MG, Thomas MJ (2016). Microdomains, inflammation, and atherosclerosis. Circ Res 118: 679–691.
103. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
104. Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ (2015). Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67: 117–127.
105. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH et al. (2013). Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 229: 174–181.
106. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF et al. (2014). Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63: 2541–2548.
107. Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P et al. (2009). Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 50: 2117–2123.
108. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R et al. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379: 1214–1224.
109. Tabas I, Bornfeldt KE (2016). Macrophage phenotype and function in different stages of atherosclerosis. Circ Res 118: 653–667.
110. Takahashi T, Takahashi K, Yamashina M, Maesawa C, Kajiwara T, Taneichi H et al. (2010). Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care 33: 463–466.
111. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P et al. (2014). Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 63: 1724–1734.
112. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C (2003). Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166: 129–135.
113. van Diepen JA, Berbee JF, Havekes LM, Rensen PC (2013). Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 228: 306–315.
114. van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA et al. (2011). The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 41: 393–400.
115. Venugopal SK, Devaraj S, Jialal I (2005). Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166: 1265–1271.
116. Viola J, Soehnlein O (2015). Atherosclerosis – A matter of unresolved inflammation. Semin Immunol 27: 184–193.
117. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K et al. (1993). 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A 90: 1369–1373.
118. Welty FK (2013). How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep 15: 400.
119. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T et al. (2011). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 342: d548.
120. Westerink J, Deanfield JE, Imholz BP, Spiering W, Basart DC, Coll B et al. (2013). High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: the PANACEA study. Atherosclerosis 227: 118–124.
121. Yamashina M, Kaneko Y, Maesawa C, Kajiwara T, Ishii M, Fujiwara F et al. (2007). Association of TNF-alpha gene promoter C-857T polymorphism with higher serum LDL cholesterol levels and carotid plaque formation in Japanese patients with type 2 diabetes. Tohoku J Exp Med 211: 251–258.
122. Yang YH, Liu YQ, Zhang L, Li H, Li XB, Ouyang Q et al. (2015). Genetic polymorphisms of the TNF-alpha-308G/A are associated with metabolic syndrome in asthmatic patients from Hebei province, China. Int J Clin Exp Pathol 8: 13739–13746.
123. Ye Q, Chen Y, Lei H, Liu Q, Moorhead JF, Varghese Z et al. (2009). Inflammatory stress increases unmodified LDL uptake via LDL receptor: an alternative pathway for macrophage foam-cell formation. Inflamm Res 58: 809–818.
124. Ye Y, Zhao X, Zhai G, Guo L, Tian Z, Zhang S (2012). Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther 17: 357–365.
125. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008). Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897–1908.
126. Zhang L, Gong D, Li S, Zhou X (2012). Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 223: 78–85.
127. Zhang YX, Cliff WJ, Schoefl GI, Higgins G (1999). Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145: 375–379.